OSAKA, Japan, May 23, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.;hereafter "Shionogi") announced that it will implement a reorganization of the Shionogi Group, including changes in responsibilities of candidates for Directors,appointment of Corporate Officers, and mergers of Group companies, as well as personnel reassignments as described below, effective July 1, 2022.
1. Change in responsibilities of candidate for directors (Effective; July 1, 2022)
New (or continuing) Position |
Name |
Present Position |
Representative Director, President and CEO |
Isao Teshirogi |
Representative Director, President and CEO |
Director and Vice Chairperson of the Board |
Takuko Sawada |
Director and Executive Vice President |
2. Appointment of Corporate Officers (Effective; July 1, 2022)
New Position |
Name |
Present Position |
Senior Executive Officer, Senior Vice President, Research Division |
Yasuyoshi Isou |
Corporate Officer, Senior Vice President, CMC R&D Division |
Corporate Officer, Senior Vice President, DX Promotion Division |
Masashi Deguchi |
Vice President, Project Management Department |
Corporate Officer, Senior Vice President, Biopharmaceutical Research Division |
Yasunori Aoyama |
Vice President, Analytical R&D Laboratory |
Corporate Officer, Senior Vice President, Integrated Disease Care Division |
Yousuke Miharu |
Vice President, New Product Planning Department |
Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division |
Takeki Uehara |
Vice President, Clinical Research Department |
3. Purpose of corporate reorganization and new establishment
In the medium-term business plan “Shionogi Transformation Strategy 2030 (STS2030),” the Shionogi Group expressed its intention to evolve from a drug-discovery-based pharmaceutical company that mainly provides ethical drugs into a HaaS (Healthcare as a Service) company that provides comprehensive healthcare services. Amid rapid changes in the business environment and in the needs of society, in order to respond flexibly to those changes and more comprehensively solve the issues facing patients and society, we must continue transforming ourselves into an organization with the ability to make prompt and effective decisions and execute efficient business operations. Based on this concept, in order to further clarify the responsibilities for business execution and to strengthen cooperation among related divisions, new supervisory organizations in charge of each major value chain (R&D, healthcare business, supply, and corporate) will be established. We will change the organization as follows, along the aforementioned lines. Organizations that are newly established or reorganized are indicated by "parentheses".
I. The R&D Supervisory Unit will oversee three divisions: “Research Division”, “Biopharmaceutical Research Division”, and Drug Development and Regulatory Science Division.
・ The Pharmaceutical Research Division and the CMC R&D Division will be reorganized into the Research Division and the Biopharmaceutical Research Division to increase the efficiency and speed of the process from drug discovery research to manufacturing method design and to advance the development of drugs with new modalities.
・ The Research Division consists of the Laboratory for Drug Discovery and Disease Research, the Laboratory for Medicinal Chemistry Research, the Laboratory for Drug Discovery and Development, the API R&D Laboratory, the Formulation R&D Laboratory, and the Intellectual Property Department.
・ The Laboratory for Bio-Drug Discovery, the Laboratory for Bio-Modality Research, and the Analysis and Evaluation Laboratory will be newly established under the Biopharmaceutical Research Division.
・ In order to further strengthen collaboration with third parties in drug discovery from the R&D stage, the "Investment Strategy Department" will be newly established to handle strategic investment outside the company, and the Business Development Department under the Corporate Strategy Division will be placed directly under the R&D Supervisory Unit.
・ The R&D functions of the Biomarker R&D Department will be incorporated into the related functions of the Research Division and the Biopharmaceutical Research Division in order to enhance their respective specialties.
II. The Healthcare Business Supervisory Unit will oversee the Pharmaceutical Commercial Division and the Inteqrated Disease Care Division.
・ The seven Pharmaceutical Promotion Departments under the Pharmaceutical Commercial Division will be reorganized into five Pharmaceutical Promotion Departments.
・ To strengthen the cooperation with the strategy planning/promotion function and sales function related to the HaaS business, the "New Business Promotion Department" will be newly established under the Integrated Disease Care Division.
・ The Regulatory Affairs Department under the Drug Development and Regulatory Science Division will be incorporated into the Healthcare Business Supervisory Unit to enhance coordination between business activities and regulatory affairs activities.
・ To promote efficient business operations from vaccine development to sales, the “Vaccine and Diagnostic Drug Department” will be newly established directly under the Healthcare Business Supervisory Unit by consolidating the Vaccine Business Department of the Inteqrated Disease Care Division and the business functions of the Biomarker R&D Department of the Pharmaceutical Research Division. Under the Vaccine and Diagnostic Drug Department, the “Diagnostic Drug Office” and the “Partnership Promotion Office” will be established.
III. The Supply Supervisory Unit will oversee the Global Business Division, overseas Group companies and production Group companies.
・ In addition to overseas Group companies and the Global Business Division, which comprises the Global Business Department and the Global Supply Chain Strategy Department, the Supply Supervisory Unit will also oversee Group companies involved in production to strengthen cooperation among all relevant companies so as to enable more efficient and flexible production and supply of products on a global basis.
IV. The Corporate Supervisory Unit will oversee the Corporate Strategy Division, the Administration Division, the DX Promotion Division, and the Corporate Quality Assurance and Ethics & Compliance Management Division.
・ Management and indirect functions previously distributed across the company will be consolidated into the Administration Division, and the “Value Chain Support Department” will be newly established. Under this new Department, the “R&D Support Office” and the “Healthcare Business Support Office” will be established to strengthen cooperation between each supervisory unit/division and headquarters.
・ Under the Human Resources Department, the “Human Capital Strategy Office” and the “Career Development Office” will be newly established.
・ The Digital Intelligence Department of the DX Promotion Headquarters will be eliminated and transferred to the relevant organization for each function.
4. Merger among Group Companies (Please refer to “Overview of the Merger” below.)
An absorption-type merger will be executed among Shionogi’s Group companies, in which Shionogi Business Partner Co., Ltd., a wholly-owned subsidiary of Shionogi, will be the surviving company and Shionogi Administration Service Co., Ltd., Shionogi Career Development Center Co., Ltd., and Shionogi Marketing Solutions Co., Ltd. will be the absorbed companies. This merger is intended to consolidate the indirect functions of these companies and eliminate duplicative functions such as management and administration, thereby creating an efficient organization that can flexibly handle fluctuations between busy and slow periods by classifying operations into two categories (those that require highly specialized expertise and abundant experience and those that do not) and establishing a system that allows flexible movement of personnel, such that, if a business is short of staff during a busy period, workers can be borrowed from other businesses.
5. Personnel Reassignments (Effective; July 1, 2022)
New (or continuing) Position |
Name |
Present Position |
|
R&D Supervisory Unit |
|||
Senior Executive Officer, Senior Vice President, R&D Supervisory Unit |
John Keller |
Senior Executive Officer, Senior Vice President, Corporate Strategy Division |
|
Vice President, Business Development Department |
Yuki Tachibana |
Laboratory for Medicinal Chemistry Research |
|
Vice President, Investment Strategy Department |
Takeaki Dohda |
DX Promotion Division |
|
Research Division |
|||
Senior Executive Officer, Senior Vice President, Research Division |
Yasuyoshi Isou |
Corporate Officer, Senior Vice President, CMC R&D Division |
|
Vice President, Laboratory for Drug Discovery and Disease Research |
Takafumi Sato |
Pharmaceutical Research Division |
|
Vice President, API R&D Laboratory |
Takayuki Tsuritani |
API R&D Laboratory |
|
President, Shionogi Techno Advance Research Co., Ltd. |
Toshiyuki Asaki |
President, Shionogi Career Development Center Co., Ltd. |
|
Biopharmaceutical Research Division |
|||
Corporate Officer, Senior Vice President, Biopharmaceutical Research Division |
Yasunori Aoyama |
Vice President, Analytical R&D Laboratory |
|
Vice President, Laboratory for Bio-Drug Discovery |
Mina Yamamoto |
Vice President, Laboratory for Innovative Therapy Research |
|
Vice President, Laboratory for Bio-Modality Research |
Akira Ino |
Vice President, API R&D Laboratory |
|
Vice President, Analysis and Evaluation Laboratory |
Izumi Ishikawa |
Shionogi Career Development Center Co., Ltd. |
|
Drug Development and Regulatory Science Division |
|||
Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division |
Takeki Uehara |
Vice President, Clinical Research Department |
|
Vice President, Project Management Department |
Shouko Kan-o |
Vice President, Research Planning Department |
|
Vice President, Clinical Research Department |
Natsuko Oda |
Clinical Research Department |
|
Healthcare Business Supervisory Unit |
|||
Senior Executive Officer, Senior Vice President, Healthcare Business Supervisory Unit and Pharmaceutical Commercial Division |
Toshinobu Iwasaki |
Senior Executive Officer, Senior Vice President, Drug Development and Regulatory Science Division |
|
Vice President, Vaccine and Diagnostic Drug Department |
Norio Tamura |
Vice President, Vaccine Business Department |
|
Senior Director, Vaccine and Diagnostic Drug Department, Diagnostic Drug Office |
Tomoyuki Yukizawa |
Vice President, Biomarker R&D Department |
|
Senior Director, Vaccine and Diagnostic Drug Department, Partnership Promotion Office |
Mikiya Takeuchi |
Vice President, Business Development Department |
|
Vice President, Tokyo Branch Office |
Junichiro Akiyoshi |
Tokyo Branch Office |
|
Pharmaceutical Commercial Division |
|||
Vice President, Pharmaceutical Commercial Division |
Yoshinori Yurugi |
Senior Director, Pharmaceutical Promotion Department - Region 3 |
|
Senior Director, Promotion Department - Region 1 |
Harumi Shimazui |
Shionogi Pharma Co., Ltd |
|
Senior Director, Promotion Department - Region 2 |
Toshiyuki Aoi |
Senior Director, Specialty Product Office |
|
Senior Director, Promotion Department - Region 3 |
Masashi Katsumata |
Senior Director, Pharmaceutical Promotion Department - Region 4 |
|
Senior Director, Promotion Department - Region 4 |
Kazuya Ishida |
Senior Director, Pharmaceutical Promotion Department - Region 5 |
|
Senior Director, Promotion Department - Region 5 |
Souichirou Mitsutake |
Senior Director, Pharmaceutical Promotion Department - Region 7 |
|
Senior Director, Specialty Product Office |
Masao Morishita |
Senior Director, Pharmaceutical Promotion Department - Region 6 |
|
Corporate Officer, Senior Vice President, Integrated Disease Care Division |
Yousuke Miharu |
Vice President, New Product Planning Department |
|
Vice President, New Product Planning Department |
Michitaka Shichijo |
Corporate Planning Department |
|
Vice President, Corporate Social Responsibility Department and President, Shionogi Smile Heart Co., Ltd. |
Hiroyuki Tanaka |
Vice President, Corporate Social Responsibility Department and Office for Children’s Bright Future |
|
Senior Director, Corporate Social Responsibility Department, Office for Children’s Bright Future |
Kumiko Masuda |
Project Management Department |
|
Vice President, New Business Promotion Department |
Hiroyuki Kobayashi |
Vice President, Digital Intelligence Department |
|
Supply Supervisory Unit |
|||
Senior Executive Officer, Supply Supervisory Unit and Global Business Division |
Koji Hanasaki |
Senior Executive Officer, Senior Vice President, Global Business Division |
|
Chairman, Shionogi Pharma Co., Ltd |
Ryuichi Kume |
President, Shionogi Pharma Co., Ltd |
|
Corporate Officer, President, Shionogi Pharma Co., Ltd |
Akira Kato |
Corporate Officer, President, Shionogi Inc. |
|
Vice President, Shionogi Pharma Co., Ltd |
Jun-ichi Hirai |
Vice President, Corporate Quality Assurance Supervisor |
|
Global Business Division |
|||
President, Shionogi Inc. |
Nathan McCutcheon |
Shionogi Inc. |
|
Corporate Supervisory Unit |
|||
Senior Executive Officer, Senior Vice President, Corporate Supervisory Unit |
Noriyuki Kishida |
Senior Executive Officer, Senior Vice President, Administration Division and Legal Affairs Department |
|
Corporate Strategy Division |
|||
Senior Executive Officer, Senior Vice President, Corporate Strategy Division and Corporate Planning Department |
Ryuichi Kiyama |
Senior Executive Officer, Senior Vice President, Pharmaceutical Research Division |
|
Vice President, Finance & Accounting Department |
Susumu Mitsumori |
Vice President, Corporate Planning Department |
|
Administration Division |
|||
Senior Executive Officer, Senior Vice President, Administration Division |
Kazuhiro Hatanaka |
Senior Executive Officer, Senior Vice President, Pharmaceutical Commercial Division |
|
Vice President, Human Resources Department and Value Chain Support Department |
Hirofumi Nagatome |
Vice President, Human Resources Department |
|
Vice President, Legal Affairs Department |
Aki Ikebata |
Legal Affairs Department |
|
Senior Director, Human Resources Department, Human Capital Strategy Office |
Takaho Kawamoto |
Human Resources Department |
|
Senior Director, Human Resources Department, Career Development Office |
Yohei Seki |
Clinical Research Department |
|
Senior Director, Value Chain Support Department, R&D Support Office |
Takeshi Sakai |
Senior Director, CMC Planning Office |
|
Senior Director, Value Chain Support Department, Healthcare Business Support Office |
Wataru Imamura |
Senior Director, Sales Planning Office |
|
President, Shionogi Business Partner Co., Ltd. |
Yuji Hosogai |
Vice President, Finance & Accounting Department |
|
DX Promotion Division |
|||
Corporate Officer, Senior Vice President, DX Promotion Division |
Masashi Deguchi |
Vice President, Project Management Department |
|
Corporate Quality Assurance and Ethics & Compliance Management Division |
|||
Corporate Officer, Senior Vice President, Corporate Quality Assurance and Ethics & Compliance Management Division |
Takeshi Shiota |
Corporate Officer, Senior Vice President, DX Promotion Division |
|
Vice President, Corporate Quality Assurance and Ethics & Compliance Management Division |
Toshio Kawakita |
Shionogi Pharma Co., Ltd |
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html
References
Summary of merger
1. Outline of merging companies
Company surviving the Merger
Shionogi Business Partner Company Limited (as of May 23, 2022)
Corporate Name |
Shionogi Business Partner Company Limited [SBP] |
Location |
7-6, Doshomachi 4-chome, Chuo-ku, Osaka |
Representative Person |
Shigeki Fujita |
The main business |
Finance and accounting, procurement, purchase, design and copies |
Initial Capitalization |
10 million yen |
Date of Establishment |
April 3, 2017 |
Number of Staff |
70 (as of March 31, 2022) |
Company absorbed in the Merger
Shionogi Administration Service Company Limited (as of May 23, 2022)
Corporate Name |
Shionogi Administration Service Company Limited [SAS] |
Location |
7-6, Doshomachi 4-chome, Chuo-ku, Osaka |
Representative Person |
Masao Kashiyama |
The main business |
Business support for the group companies such as human resources, general administration and internal communications |
Initial Capitalization |
10 million yen |
Date of Establishment |
November 2, 1992 |
Number of Staff |
180 (as of March 31, 2022) |
Shionogi Career Development Center Company Limited (as of May 23, 2022)
Corporate Name |
Shionogi Career Development Center Company Limited [SCD] |
Location |
829-1 Tonouchi, Amagasaki, Hyogo |
Representative Person |
Toshiyuki Asaki |
The main business |
1.Career development and support, planning and pursuing career development programs for the Group companies 2.Planning, operation and evaluation of training and development 3.Planning and operation of professional education for each division of Shionogi such as education for new or current sales representatives, globally-focused education |
Initial Capitalization |
10 million yen |
Date of Establishment |
April 3, 2017 |
Number of Staff |
26 (as of March 31, 2022) |
Shionogi Marketing Solutions Company Limited (as of May 23, 2022)
Corporate Name |
Shionogi Marketing Solutions Company Limited [SMS] |
Location |
3-13, Imabashi 3-chome, Chuo-ku, Osaka |
Representative Person |
Minoru Mitsuda |
The main business |
1.1Commercial data analysis, sales data management and market research 2.Communication design and creation and management of commercial tools 3.Supporting events such as academic lectures |
Initial Capitalization |
10 million yen |
Date of Establishment |
April 3, 2017 |
Number of Staff |
71 (as of March 31, 2022) |
2. Status after the merger
Corporate Name |
Shionogi Business Partner Company Limited [SBP] |
Location |
7-6, Doshomachi 4-chome, Chuo-ku, Osaka |
Representative Person |
Yuji Hosogai |